About Us
Kalohexis is a clinical-stage biotechnology company shaping the next era of metabolic disease care.
At Kalohexis, we are shaping the next era of metabolic disease care by harnessing the melanocortin system to develop first-in-class and best-in-class treatments. The melanocortin system is the body’s natural regulator of metabolic homeostasis but has been misunderstood and suboptimally targeted in the past. With more than a decade of expertise in melanocortin biology, our team developed a proprietary pipeline of therapeutic peptides designed to safely and effectively drug central melanocortin 3 and 4 receptors (MC3R/MC4R) to treat metabolic disorders, such as obesity and cancer cachexia, and help people live healthier lives.
Leadership
Russell Potterfield, M.B.A.
CHIEF EXECUTIVE OFFICER
Daniel Marks, M.D., Ph.D.
Chief Medical and Scientific Officer
Tony Mitchell, M.B.A.
CHIEF FINANCIAL OFFICER
Barry Badeau, Ph.D.
Chief Development Officer
Jordan Delev
Chief Discovery Officer